A citation-based method for searching scientific literature

Rozita Bagheri-Yarmand, Naifa L Busaidy, Elena McBeath, Brian P Danysh, Kurt W Evans, Tyler J Moss, Argun Akcakanat, Patrick K S Ng, Christina M Knippler, Jalyn A Golden, Michelle D Williams, Asha S Multani, Maria E Cabanillas, Kenna R Shaw, Funda Meric-Bernstam, Manisha H Shah, Matthew D Ringel, Marie Claude Hofmann. Cancers (Basel) 2021
Times Cited: 4







List of co-cited articles
23 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
431
100


Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
385
75

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
75

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
186
75

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
877
75

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.
Cristina Montero-Conde, Sergio Ruiz-Llorente, Jose M Dominguez, Jeffrey A Knauf, Agnes Viale, Eric J Sherman, Mabel Ryder, Ronald A Ghossein, Neal Rosen, James A Fagin. Cancer Discov 2013
269
75

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
Gerald S Falchook, Michael Millward, David Hong, Aung Naing, Sarina Piha-Paul, Steven G Waguespack, Maria E Cabanillas, Steven I Sherman, Bo Ma, Martin Curtis,[...]. Thyroid 2015
128
50

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean Jacques Grob,[...]. N Engl J Med 2014
50

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Marcia S Brose, Bruce Robinson, Steven I Sherman, Jolanta Krajewska, Chia-Chi Lin, Fernanda Vaisman, Ana O Hoff, Erika Hitre, Daniel W Bowles, Jorge Hernando,[...]. Lancet Oncol 2021
51
50

Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.
Maria E Cabanillas, Ramona Dadu, Pryianka Iyer, Kacey B Wanland, Naifa L Busaidy, Anita Ying, Maria Gule-Monroe, Jennifer R Wang, Mark Zafereo, Marie-Claude Hofmann. Thyroid 2020
28
50

Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Brian P Danysh, Erin Y Rieger, Deepankar K Sinha, Caitlin V Evers, Gilbert J Cote, Maria E Cabanillas, Marie-Claude Hofmann. Oncotarget 2016
37
50

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
Kevin B Kim, Maria E Cabanillas, Alexander J Lazar, Michelle D Williams, Deborah L Sanders, Joseph L Ilagan, Keith Nolop, Richard J Lee, Steven I Sherman. Thyroid 2013
144
50

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
211
50

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
50

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
50

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
216
50

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
685
50

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Husain Yar Khan, James Ge, Misako Nagasaka, Amro Aboukameel, Gabriel Mpilla, Irfana Muqbil, Mark Szlaczky, Mahmoud Chaker, Erkan Baloglu, Yosef Landesman,[...]. Int J Mol Sci 2019
13
50

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
Dwight H Owen, Bhavana Konda, Jennifer Sipos, Tom Liu, Amy Webb, Matthew D Ringel, Cynthia D Timmers, Manisha H Shah. J Natl Compr Canc Netw 2019
20
50

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
877
50

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
Priyanka C Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D Williams, G Brandon Gunn, Horiana Grosu,[...]. J Immunother Cancer 2018
101
50

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
574
50

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Jeffrey R Infante, Leslie A Fecher, Gerald S Falchook, Sujatha Nallapareddy, Michael S Gordon, Carlos Becerra, Douglas J DeMarini, Donna S Cox, Yanmei Xu, Shannon R Morris,[...]. Lancet Oncol 2012
374
25

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
476
25


Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
Paolo Salerno, Valentina De Falco, Anna Tamburrino, Tito Claudio Nappi, Giancarlo Vecchio, Rebecca E Schweppe, Gideon Bollag, Massimo Santoro, Giuliana Salvatore. J Clin Endocrinol Metab 2010
81
25

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
Rebecca Leboeuf, Jacqueline E Baumgartner, Miriam Benezra, Roberta Malaguarnera, David Solit, Christine A Pratilas, Neal Rosen, Jeffrey A Knauf, James A Fagin. J Clin Endocrinol Metab 2008
103
25

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Fabrice Barlesi, Pierre-Jean Souquet, Egbert F Smit, Harry J M Groen, Ronan J Kelly,[...]. Lancet Oncol 2016
266
25

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
25

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
David G McFadden, Amanda Vernon, Philip M Santiago, Raul Martinez-McFaline, Arjun Bhutkar, Denise M Crowley, Martin McMahon, Peter M Sadow, Tyler Jacks. Proc Natl Acad Sci U S A 2014
94
25

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novello,[...]. Lancet Oncol 2016
500
25

The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).
Joanna Xing, Ruixin Liu, Mingzhao Xing, Barry Trink. Biochem Biophys Res Commun 2011
41
25

miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
Zhenhua Hu, Mingbo Cai, Ying Zhang, Lingling Tao, Ruixia Guo. Cell Cycle 2020
46
25

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Alain Ravaud, Christelle de la Fouchardière, Philippe Caron, Adelaïde Doussau, Christine Do Cao, Julien Asselineau, Patrice Rodien, Damien Pouessel, Patricia Nicolli-Sire, Marc Klein,[...]. Eur J Cancer 2017
66
25

Cancer-Associated Fibroblasts Positively Correlate with Dedifferentiation and Aggressiveness of Thyroid Cancer.
Shishuai Wen, Ning Qu, Ben Ma, Xiao Wang, Yi Luo, Weibo Xu, Hongyi Jiang, Yan Zhang, Yu Wang, Qinghai Ji. Onco Targets Ther 2021
12
25

Combination Treatment with the BRAFV600E Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma.
Ju Hye Jeong, Ji Min Oh, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Byeong-Cheol Ahn. Thyroid 2019
12
25

The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma.
Zhongqiang Zhang, Xiao Tan, Jing Luo, Hongliang Yao, Zhongzhou Si, Jing-Shan Tong. Cell Death Dis 2020
33
25

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells.
Teresa Di Desidero, Paola Orlandi, Daniela Gentile, Guido Bocci. Front Oncol 2019
8
25

Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer.
Jing Zhai, Jiajia Shen, Guiping Xie, Jiaqi Wu, Mingfang He, Lili Gao, Yifen Zhang, Xuequan Yao, Lizong Shen. Cancer Lett 2019
87
25

Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells.
Fiorenza Gianì, Giulia Russo, Marzio Pennisi, Laura Sciacca, Francesco Frasca, Francesco Pappalardo. Bioinformatics 2019
16
25

TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel.
Jie Tan, Rengyun Liu, Guangwu Zhu, Christopher B Umbricht, Mingzhao Xing. Proc Natl Acad Sci U S A 2020
19
25

A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
Soo-Ryum Yang, Umut Aypar, Ezra Y Rosen, Douglas A Mata, Ryma Benayed, Kerry Mullaney, Gowtham Jayakumaran, Yanming Zhang, Denise Frosina, Alexander Drilon,[...]. Clin Cancer Res 2021
18
25

Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect.
Luyuan Ma, Wenpeng Liu, An Xu, Quanbo Ji, Yongfu Ma, Yanhong Tai, Yadong Wang, Chuan Shen, Ying Liu, Tao Wang,[...]. Cancer Sci 2020
12
25

YAP confers resistance to vandetanib in medullary thyroid cancer.
Huan Wang, Jian Tang, Zhiwei Su. Biochem Cell Biol 2020
4
25

Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer.
Seok-Mo Kim, Soo Young Kim, Cheong Soo Park, Hang-Seok Chang, Ki Cheong Park. Cancers (Basel) 2020
5
25

The association of AMPK with ULK1 regulates autophagy.
Jong Woo Lee, Sungman Park, Yoshinori Takahashi, Hong-Gang Wang. PLoS One 2010
353
25


Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Su In Lee, Dae Kyoung Kim, Eun Jin Seo, Eun Jung Choi, Yang Woo Kwon, Il Ho Jang, Jin Choon Lee, Hyun Yul Kim, Minho Shong, Jae Ho Kim,[...]. Thyroid 2017
13
25

Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.
Zhenyu Xie, Xin Li, Yuzhen He, Song Wu, Shiyue Wang, Jianjian Sun, Yuchen He, Yu Lun, Jian Zhang. Front Endocrinol (Lausanne) 2020
31
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.